BioCentury | Sep 13, 2019
Distillery Therapeutics

CXCL10-CXCR3 axis inhibition to block brain metastasis from melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Inhibiting the chemoattractant CXCL10 or its receptor CXCR3 could prevent melanoma from forming brain metastases. Levels of CXCL10 mRNA were higher in metastases-associated astrocytes isolated from mice with melanoma than...
BioCentury | Mar 20, 2014
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Chemokine CXC motif ligand 10 (CXCL10; IP-10); CXC chemokine receptor 3 (CXCR3) Human sample and mouse studies suggest inhibiting CXCL10 could help...
BioCentury | Oct 3, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Chemokine CXC motif ligand 10 (CXCL10; IP-10) In vitro and mouse studies suggest antibodies targeting CXCL10 could help treat breast cancer. In human...
BioCentury | Jul 27, 2009
Strategy

Medarex pipeline

Medarex pipeline Therapeutics Product [Partner] Target Status [Lead indication] Ipilimumab (MDX-010) [Bristol-Myers Squibb Co. (NYSE:BMY)] CTLA-4 (CD152) receptor Ph III [melanoma] MDX-1100 Chemokine CXC motif ligand 10 (CXCL10) (IP-10) Ph II [rheumatoid arthritis (RA); ulcerative...
BioCentury | Jul 27, 2009
Company News

Medarex, Bristol-Myers deal

Bristol-Myers plans to acquire Medarex in a tender offer of $16 per share, or about $2.4 billion in cash. Bristol-Myers said it expects Medarex to have $300 million in net cash at closing. The price...
BioCentury | May 18, 2009
Finance

Ebb & Flow

Just after reporting its first profitable quarter, respiratory specialist Cornerstone Therapeutics Inc. (NASDAQ:CRTX) decided to exchange half the company for the right to become the U.S. marketing arm of Italian drug company Chiesi Farmaceutici S.p.A....
BioCentury | May 18, 2009
Clinical News

MDX-1100: Phase II data

Top-line data from a double-blind, European Phase II trial in 70 patients showed that 10 mg/kg MDX-1100 every 2 weeks met the primary endpoint of a significant improvement in ACR20 at week 12 vs. placebo...
BioCentury | May 15, 2009
Clinical News

Medarex's MDX-1100 meets Phase II endpoint

Medarex Inc. (NASDAQ:MEDX) said top-line data from a Phase II trial showed that 10 mg/kg MDX-1100 every two weeks met the primary endpoint of a significant improvement in ACR20 at week 12 vs. placebo (p=0.0024)....
BioCentury | May 19, 2008
Clinical News

MDX-1100: Phase II started

Medarex began a double-blind, placebo-controlled, international Phase II trial to evaluate 10 mg/kg MDX-1100 given every other week for 8 weeks in 106 patients. Medarex Inc. (NASDAQ:MEDX), Princeton, N.J. Product: MDX-1100 Business: Autoimmune Molecular target:...
BioCentury | May 19, 2008
Clinical News

MDX-1100: Phase II started

Medarex began a double-blind, placebo-controlled, European Phase II trial to evaluate 10 mg/kg MDX-1100 given every other week for 12 weeks in about 70 patients. Medarex Inc. (NASDAQ:MEDX), Princeton, N.J. Product: MDX-1100 Business: Autoimmune Molecular...
Items per page:
1 - 10 of 12